Filtered By:
Condition: SARS
Infectious Disease: Zika Virus
This page shows you your search results in order of date.
Order by Relevance | Date
Total 23 results found since Jan 2013.
The U.S. Scientist At the Heart of COVID-19 Lab Leak Conspiracies Is Still Trying to Save the World From the Next Pandemic
Ralph Baric stepped onto the auditorium stage at the University of North Carolina, Chapel Hill, and looked out at the sparse audience that had come to hear him speak. On the large projector screen hanging behind him, the following words appeared: How Bad the Next Pandemic Could Be, What Might It Look Like, and Will We be Ready. The date was May 29, 2018.
“Well, I have to admit I’m a little worried about giving this talk,” Baric said. “The reason is being labelled a harbinger of doom.” The screen shifted, and images of the four horsemen of the apocalypse—Death, Famine, War, and Plague&mda...
Source: TIME: Health - July 11, 2023 Category: Consumer Health News Authors: Dan Werb Tags: Uncategorized COVID-19 feature freelance Source Type: news
Dr. Anthony Fauci Is Stepping Down. Here ’s His Advice For His Successor
After Dr. Anthony Fauci steps down as head of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden on Dec. 31, he’ll leave behind a long and storied career. Ahead of his last day, he spoke to TIME from his office at the National Institutes of Health about what’s next for him—and his advice for whoever fills his shoes.
This interview has been edited and condensed for clarity.
TIME: You’re leaving your leadership positions in the federal government, but you aren’t retiring. What are you calling the next stage in your career?
[time-brightc...
Source: TIME: Health - December 20, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
News at a glance: New gene therapy, Europe ’s drought, and a black hole’s photon ring
ARCHAEOLOGY
Drought exposes ‘Spanish Stonehenge’ for study
Scientists are rushing to examine a 7000-year-old stone circle in central Spain that had been drowned by a reservoir for decades and was uncovered after the drought plaguing Europe lowered water levels. Nicknamed the “Spanish Stonehenge”—although 2000 years older than the U.K. stone circle—the Dolmen of Guadalperal (above) was described by archaeologists in the 1920s. The approximately 100 standing stones, up to 1.8 meters tall and arranged around an oval open space, were submerged in the Valdecañas reservoir after the construction of a ...
Source: Science of Aging Knowledge Environment - August 25, 2022 Category: Geriatrics Source Type: research
He battled AIDS, COVID-19, and Trump. Now, Anthony Fauci is stepping down
Anthony Fauci, the renowned physician-scientist who has led the $6.3 billion National Institute of Allergy and Infectious Diseases (NIAID) for nearly 4 decades and since early 2020 has been the U.S. government’s voice of scientific reason during the COVID-19 pandemic, will step down from government service in December.
Fauci, 81, had said in
recent interviews
that he planned to retire from the government by the end of President Joe Biden’s administration, but did not give a date until today. He said in a
statement
that although leading NIAID “has been the honor of a lifetime,” he plans to “pursue...
Source: Science of Aging Knowledge Environment - August 22, 2022 Category: Geriatrics Source Type: research
Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants ...
Source: Johnson and Johnson - April 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Spring 2021 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities & Related Notices
NIH/HHS News
Subscribe to NICDR News
Science Advances
Grantee News
NIDCR News
NIDCR & NIH Stand Against Structural Racism
NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH initiative—called UNIT...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news
Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe today’s re...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3
ENSEMBLE
clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
What Will The COVID-19 Vaccine Feel Like?
(CNN) — As the United States inches closer to authorizing a COVID-19 vaccine, many people may now let themselves start wondering what it will feel like to get it.
Is it going to be like the flu vaccine? Will it be more painful? And what about side-effects?
The two front-runners for getting an emergency use authorization from the US Food and Drug Administration — Pfizer/BioNTech and Moderna — use new mRNA technology. No U.S.-licensed vaccine has ever used it, although researchers have been studying it for decades against infections like flu, rabies and Zika, and even for some types of cancer.
The way these...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 3, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Covid-19 Boston, MA Healthcare Status News Coronavirus Moderna Therapeutics Pfizer Source Type: news
U.K. Plans ‘Challenge Trials,’ Which Will Intentionally Give People COVID-19 to Test Vaccines
On Oct. 20, researchers at the Imperial College of London announced plans for the first human challenge study of COVID-19, which involves deliberately infecting volunteers with the virus that causes the disease, in order to test the effectiveness of vaccines.
The strategy is controversial, as researchers have to weigh the risks of infection against the benefits of learning how well the various vaccine candidates can fight that infection. The strongest argument in favor of the studies has to do with time. If cases of COVID-19 are waning, then the likelihood that people who are vaccinated would get exposed to and potentially...
Source: TIME: Health - October 20, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Johnson & Johnson Announces European Commission Approval for Janssen ’s Preventive Ebola Vaccine
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vaccine regimen ori...
Source: Johnson and Johnson - July 1, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
